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Antigen-dependent activation of T cells occurs through the 
T-cell antigen-receptor complex (TCR/CD3). Antigen-in-
dependent T-cell activation may occur through the surface 
molecules CDw60, CD2, and CD28. We wished to deter-
mine whether these antigen-independent T -cell- activation 
pathways could be involved in proliferation of leukemic 
T cells from patients with cutaneous T-cell lymphoma 
(CTCL). Whereas CDw60 was only expressed on 28% ± 
7% (mean ± SEM) of blood T cells obtained from healthy 
control subjects (n = 4), CDw60 was expressed on 94% ± 
30/0 of blood T cells obtained from patients with CTCL (n = 
4). Dual color immunofluorescence microscopy of the T-cell 
infiltrate in involved skin of these patients demonstrated that 
almost 100% of the T cells expressed CDw60. Not only did 
T cells in the patients with CTCL express CDw60, but trig-
gering of the T cells with anti-CDw60 resulted in enhanced 
C utaneous T-cell lymphomas (CTCL) are neoplasms of T cells that primarily affect the skin [1 J. Sezary syndrome is a leukemic variant of CTCL character-ized by erythroderma, pruritus, lymphadenopathy, and circulating atypical, presumably malignant T 
cells with cerebriform nuclei [2]. The skin lesions in CTCL contain 
a polymorphic cell infiltrate comprised of both malignant T cells 
~nd non-malignant tumor-infiltrating T lymphocytes (TIL), as well 
)5 macrophages, Langerhans cells, and other inflammatory cells 
\1,3}. 
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Abbrevia tions: 
Con A: Concanavalin 
CTCL: cutaneous T-celllymphoma(s) 
proliferation relative to anti-TCR/CD3 and mitogenic lec-
tins. Other antigen-independent pathways also appeared 
highly active in the T cells from patients with CTCL because 
enhanced proliferation relative to anti-TCR/CD3 or mito-
genic lectins was found when anti-CD2 or anti-CD28 plus 
phorbol ester was used as stimulant. Despite the brisk prolif-
eration induced by anti-CDw60, anti-CD2, or anti-CD28, T 
cells from the patients did not produce detectable amounts of 
y-interferon. T he inability to produce y-interferol1 correlates 
with our finding of absent (n = 3) or weak (n = 1) intercel-
lular adhesion molecule-l expression in the lesional keratino-
cytes in these patients. In conclusion, T cells of patients 
with CTCL demonstrate elevated expression of a T -cell -
independent signaling molecule CDw60 and respond to 
antigen-independent activating signals. ] In vest Dermatol 
100:667-673,1993 
Whereas CTCL T[L may be responsive to antigen-receptor-
dependent signaling provided by hyperstimulatory antigen-
presenting Langerhans cells present in involved epidermis [4J, the 
malignant clone may proliferate and achieve its activated state 
through alternative antigen-independent activation pathways. An-
tigen-independent pathways that might be involved in activation of 
the malignant T cells include ligand triggering of molecules, such as 
CDw60 [5J, CD2 [6J, and CD28 [7J. Ligands for both CD2 and 
CD28 have been identified as lymphocyte function-associated an-
ti gen (LFA)-3 and B7/BB-1, respectively (8,9]. LFA-3 is expressed 
ICAM-l: in tercellular adhesion molecule-l 
HLA: human leukocyte antigen 
Ig: immunoglobul in 
IL-2: interl eukin-2 
LFA: lymphocyte functio n-associated antigen-l 
MNC: mononuclear cell(s) 
PH A: phytohaemagglutinin 
PMA: phorbol myristate acetate 
TCR: T-cell receptor 
[3HJthymidine: TdR 
TIL: tumor-infiltrating T lymphocytes 
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Table I. Clinical Characteristics of Four Male Patients with CTCL 
Total Bone 
Age Leucocyte Clinical Marrow TCR 
Patient (years) Count" Statusb Involvement' TNM Rearrangement' 
1 71 50.0 3,4 + T,NoMoB, + 
2 55 16.0 1,3-9 NO T.N)MoB, + 
3 65 23.0 1,3-6,9 + T.N)MoB, + 
4 72 11.0 1-4,6,8,9 T.NoMoB, + 
• Normal leucocyte range 3.0 - 9.0 X 109/1. 
• I, erythroderma; 2, hepatomegaly; 3, skin plaque or tumor; 4, intense pruritus; 5, adenopathy; 6, alopecia; 7, onychodystrophy; 8, keratoderma of palms and soles; 9, ectropion 
with resultant ocular inflam_macion. 
, (+) Present; (-) not present; NO, not done. 
J Presence of T-cell receptor (TCR) p gene rearrangement (non - germ-line bands) in both the skin and peripheral blood; (+) present. 
on both keratinocytes and Langerhans cells [10], as may be B7 .H 
The ligand for CDw60 has not yet been identified. The responses of 
leukemic blood T cells frorn,patients with CTCL to various T-cell 
antigen-independent stimuli were therefore compared with anti-
gen-dependent stimuli. 
MATERIALS AND METHODS 
Patients Four untreated patients with clinical, laboratory, and 
histologic features of CTCL and four healthy adult control subjects 
participated in the study (Table I). Each patient had evidence of 
blood involvement by peripheral smear and Southern blot analysis. 
Patient 1 was characterized as having leukemic CTCL and patients 
2-4 as having Sezary syndrome. 
Immunohistochemistry Skin biopsies were taken from in-
volved skin of four patients with CTCL and were immediately 
snap-frozen and stored in liquid nitrogen. Immunohistologic stain-
ing was performed on cryostat sections using a three-stage biotin-
avidin horseradish peroxidase procedure, as previously described 
[11]. A panel of antibodies was applied to each biopsy (Table II). 
Anti-CDw60 was diluted 1: 200 and anti-CD28 1: 50; all other 
antibodies were diluted 1: 10. The specificity of the monoclonal 
antibodies used in the staining procedures was verified by use of 
irrelevant isotype antibodies, GFAP and Gp lIb/lIla (Table II). Sec-
tions of tonsil and lymph nodes were used as positive controls for the 
antibodies. The slides were counterstained with hematoxylin/eosin 
and scored in a blinded fashion. In each section, 150 cells of the 
lymphohistiocytic infiltrate were analyzed; the number of cells ex-
pressing the respective antigen is given in percent of infiltrating 
cells. 
Immunofluorescence Staining Blood mononuclear cells 
(MNC) were stained by a two-stage procedure [4]. The primary 
antibodies were used in a 1: 10 dilution. As secondary antibody, 
rhodamine-conjugated goat anti-mouse immunoglobulin (Ig) at a 
dilution of 1 : 100 (Dakopatts, Copenhagen, Denmark) was used. 
Double color immunofluorescence microscopy ofT cells in the skin 
was performed by using rhodamine-conjugated goat anti-mouse 
IgM (Tago Inc., Burlingham, CA) to visualize anti-CDw60 (IgM 
antibody), and fluorescein-conjugated goat anti-mouse IgG (Kirke-
gaard, Gaithersburg, V A) to visualize the co-staining anti-CD3. 
Peripheral blood T cells were double-stained using rhodamine-con-
jugated goat anti-mouse IgM (Serotec, Oxford, England) and fluo-
rescein-conjugated goat anti-mouse IgG 1 (Ser,otec). To control for 
cross-reactivity and non-specific binding of the second antibodies, 
irrelevant primary isotype antibodies GFAP and Gp lIb/IlIa were 
substituted for anti-CD3 or anti-CDw60. The sections were evalu-
ated by an immunofluorescence microscope equipped with epi-illu-
mination and appropriate filter. 
t t Fleming TE, Mirando WS, Elmets CA: Expression of the activation 
antigen BB-1/B7 on cells of non-hematopoietic origin: keratinocytes from 
human epidermis (abstr). J Invest Dermatol 98:577 A, 1992. 
T-Cell Activation Fifty-thousand MNC were incubated with 1 
)lg/ml phytohaemagglutinin (PHA) (Wellcome Diagnostics, Dart-
ford, England), 10 )lg/ml Concanavalin A (Con A) (Calbiochem 
Corp., San Diego, CA), pokeweed mitogen (1 : 200) Gibco, Grand 
island, NY) , anti-CDw60 (1: 200), a mitogenic pair of anti-C02 
(lmon02A6 and 10LD24Cl, each at 1: 500), anti-CD2 (1: 250), 
anti-CD28 (1: 200), anti-T-cell receptor (TCR)-l (1: 250), anti-
CD3 (1: 500), or 50-U recombinant interleukin-2 (IL-2) (Amer-
sham, Arlington Heights, IL), with or without phorbol myristate 
acetate (PMA) (Sigma, St. Louis, MO) at 3 ng/ml in 200 )lJ RPM! 
1640 with 10% AB serum, glutamine, and antibiotics. The cultures 
were pulsed after 48, 72, or 96 h with 1 )lCi of [3HJthymidine 
(TdR)/well and were harvested 18 h later on a cell harvester (Tek-
nunc, Roskilde, Denmark); TdR incorporation was measured with 
a liquid scintillation counter. 
Determination of y-Interferon The supernatants were tested 
for production of y-interferon after 48 h of incubation with mito-
genic lectins or antibodies, as mentioned above, with commercial 
enzyme-linked immunosorbent assay kits (y-interferon; Holland 
Biotechnology, Leiden, The Netherlands). 
Table II. Monoclonal Antibodies 
CD4 
CD8 
CD3 
C02 
Antibody 
T1l z (1mon02A6) 
Ttl) (10LD24Cl) 
HLA-DR 
Leu-M3 
CD19 
CD25 (anti-Tac) 
TCR 
CDw60 (UM4D4) 
CD28 
CD45RO (UCHLl) 
CDR45RA (2H4) 
ICAM-l 
GFApJ 
Gp lib/IlIa 
Specificity 
T-helper cel ls 
T -su ppressor / cytotoxic cells 
Pan T cell 
Pan T cell (Erythrocyte rosette 
receptor) 
Pan T cell (Erythrocyte rosette 
receptor) 
Pan T cell (Erythrocyte rosette 
receptor) 
HLA-DR (class II antigens) 
Monocytes/macrophages 
Pan B cells 
IL-2 receptor 
TCR antigen complex 
A subset of T cells 
80% ofT cells 
Higher expression on CD4+ 
helper/memory T cel ls 
Higher expression on CD4+ 
suppressor/inducer T cel ls 
Intercellular adhesion molecule-l 
Acidic protein in brain and 
spinal cord 
Human platelets 
Source' 
BD/DAKO 
BD/DAKO 
BD/DARO 
BD/DAKO 
DAKO 
BD 
DAKO 
BD/DAKO 
BD 
OWN 
DAKO 
CC 
S 
DAKO 
DAKO 
• BD, Becton Dickinson Co., Mountain View, CA; CC, Coulter C lone, Hialeah, FL; 
DAKO, Dakopatts, Copenhagen, Denmark; S, Serotec, Oxford, England. 
• Kindly provided by Drs. Ellis Reinherz and Stuart Schlossman, Dana Farber Canc<! 
Institute, Boston, MA. 
, Kindly provided by Dr. Laurence Turk., Universiry of Michigan, Ann Arbor MI. 
, Glial fibrillary acidic protein. ' 
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Table llI. lmmunophenotyping of the Lymphohistiocytic 
Dermal Infiltrate in Skin Biopsies from Patients with CTCU 
Patient Number 
2 3 4 
CD4 +++ +++ +++ ++ 
CDB + + ++ 
CD2 +++ ++ +++ +++ 
CD3 +++ +++ +++ +++ 
CD45RO +++ +++ +++ +++ 
CD45RA + + 
CD28 +++ ++ ++ ++ 
CD19 
CD25 + 
CDw60 +++ +++ +++ +++ 
HLA-DR ++ ++ ++ ND 
l.eu-M3 
• (+) Sections with < 10% positive cells; (++) between 10% and 80%; (+++) > 
80%; (-) negative for the respectIve antIgen. 
Skin-Derived T-Cell Clones Six-millimeter skin-punch biop-
sies were obtained from involved skin of a patient with tumor-stage 
mycosis fungoides-type CTCL and from a patien.t with. CTCL. The 
biopsies were cut hOrizontally, as cl?se to the epidermis ~s pOSSIble, 
and then cut into several 1-mm pieces and 1I1cubated 111 24-well 
culture plates containing RPMI-1640 culture medium with 10% 
!ill serum, 10% purified IL-2 (Electro-Nucleonics, Cell Science 
laboratory, Silver Spring, MD), glutamine, and antibiotics at 37 ° C. 
Following 24 h of incubation, T cells were cloned using limiting 
dilution, as previously described [3] . 
'l'.Cell Lines from Peripheral Blood One-million MNC/ml 
obtained from a patient with CTCL and a healthy subject were 
Ilimulated with 1 ,ug/ ml PHA (Welcome) and 3 ng/ml PMA 
(Sigma) for 24 h. The cells were then extensively washed and cul-
tured at a concentration of 1 X 106 celIs/ml in RPMI-1640 culture 
medium with 10% AB serum, 10% purified IL-2 (Electro-Nu-
cleonics) , glutamine, and antibiotics at 37°C. The medium was 
changed twice weekly. When ceIl density was greater than 1 X 106 
cells/ml, the celJ cultures were split. After 1-3 weeks in culture, 
without repeated stimulation with PHA/PMA, analysis of CDw60 
antigen was performed with a Becton Dickinson fluorescence-acti-
vated cell sorter IV flow cytometer. Anti-CDw60 was identified 
with fluorescein-conjugated goat anti-mouse Ig (Becton Dickin-
IOn) . Analysis was performed on 10,000 cells, and the acquired data 
Were expressed as percent of CDw60+ cells. 
TCR Gene Rearrangement Southern blot analysis to detect 
rearrangement of the p-chain of the TCR was performed as previ-
OUsly described [3] . 
RESULTS 
Lymphohistiocytic Infiltrate in Skin of Patients with CTCL 
Is DOIIlinated by CD4+ CD45RO+ "Memory" T-Helper 
Cells That Also Express the CDw60 T-Cell-Activating 
Molecule To determine potential T-cell activation pathways in 
patients w ith CTCL, we examined activating molecules on T cells 
in the cellular infiltrate of the skin and in the peripheral blood. 
T~ble III depicts immunophenotyping of involved skin from the 
patients. In all specimens, CD3+ CD2+ T cells dominated. The 
dmse bandlike dermal T-cell infiltrate was composed of CD4+ 
CD45RO+ "memory" T-helper cells. CD45RA + T cells and CD8+ 
T cells were found only scattered within the infiltrate. A high 
~rcentage of the T cells were activated because they expressed the 
human leukocyte antigen (HLA)-DR class II antigen. Despite the 
<ctivated s tate, only patient 3 demonstrated some expression ofIL-2 
r~eptor (CD25). CD19+ B cells and Leu-M3+ monocytes/macro-
Phages were only occasionally seen.. . 
Activated T cells normally produce Y-1I1terferon, which upregu-
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lates intercellular adhesion molecule (ICAM)-l; however, except 
for focal expression in patient 4, ICAM-l (CD 54) epidermal ex-
pression was absent. O ccasional MNC in the dermis stained positive 
for ICAM-l in patients 2 and 3 (data not shown). 
Double immunofluorescence microscopy revealed that nearly 
100% of the CD3+ T cells in lesional skin co-expressed the CDw60 
molecule (Fig 1). 
CDw60 Expression on Malignant T Cells In the peripheral 
blood from the patients with CTCL, the mean number of CDw60+ 
cells was 94% ± 3% (mean ± SEM; n = 4) (Fig Ib; Table IV). In 
contrast, the expression of CDw60 on T cells in healthy control 
subjects was only 28% ± 7% (n = 4). 
Because nearly 100% of the lesional and peripheral blood T cells 
express CDw60, it is very likely that the malignant T cells express 
the molecule. To test this hypothesis, analysis of TCR gene rear-
rangements were .performed to verify that a significant proportion 
of the cells compmed the malIgnant monoclonal T-cell population . 
DNA samples of both the blood and skin from patient 1 were 
digested with HindIII or EcoRl and hybridized to a probe for the 
constant region of the TCRP to detect TCR p-chain gene rearrange-
ments. As indicated on the Southern blot, the same rearranged bands 
both in the blood and the skin following HindIII digestion (Fig 2, 
arrows) and the near disappearance of the 12-kbp band both in the 
blood and skin following EcoR1 digestion demonstrate that the 
majority of the T cells in the blood and in the skin have the same 
TCR gene rearrangement and thus belong to the same clone. 
Thus, CDw60 is expressed on malignant T cells because nearly 
100% of the T cells express the molecule, and a majority of the 
T cells belong to a monoclonal population. 
Non-Malignant Tumor-Infiltrating T Cells Derived from 
Patients with CTCL Demonstrate Normal Expression of 
CDw60 To demonstrate whether an enhanced expression of 
CDw60 also was present on tumor-infiltrating T cells, T cell s ob-
tained from the blood of patient 1 were cultured for 4 weeks in the 
presence. of IL-2, PHA, and PMA. TCR gene rearrangement per-
formed 1tl the cells after 1 - 4 weeks in culture revealed that the 
malignant clone was gradually replaced by other clones, as indicated 
by the disappearance of the TCR gene rearrangement (Fig 3a). 
Staining with anti-CDw60 demonstrated that the level of expres-
sion on the T cells decreased sllTIultaneously with replacement of 
the malignant clone with non-malignant TIL (Fig 3b). Thirteen 
tumor-infiltrating T-cell clones obtained from the skin of the same 
patient were also stained with anti-CDw60. The expression of 
CDw60 (38% ± 8%, mean ± SEM) was comparable to that ob-
served in normal blood T cells (Table IV) and in T-cell clones 
obtained from healthy peripheral blood [5]. In addition, 21 tumor-
infiltrating T-cell clones obtained from a patient with mycosis fun-
goides in tumor stage demonstrated a mean of 25% CDw60+ T 
cells, despite a high level of CDw60 expression on the T cells in the 
tumor nodule (data not shown). 
Anti-CDw60 as a Single Stimulus Potently Activates Blood 
T ~ells from Pati~nts with Leukemic CTCL Because patients 
With CTCL contalIled a high number of CDw60+ malignant T 
cells, we determined w hether this molecule was involved in activa-
tion of the T cells. Proliferation in response to stimulation with 
an.tl-CD~60 vo.:as therefore compared with the response to various 
Imtogel11c lect1l1s and T-cell surface molecules known to be in-
volved in T-cell activation. 
To determine the optimal time point for anti-CDw60 activation, 
a time study on the T cells from the patients with CTCL was 
performed. TdR incorporation reached a maximum after 48 h of 
culture, after which the incorporation decreased. In the following 
experiments, TdR incorporation was performed after 48 h of cul-
ture. 
Consistent with the findings of others [1 2 -17J, patients with 
CTCL responded poorly or not at all to mitogenic plant lectins, 
including PHA, Con A, and PWM. Similar results were obtained 
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Figure 1. a) Double indirect immunofluorescence microscopy 
of a tumor nodule in the dermis from a patient with CTCL 
stained with anti-CD3 and anti-CDw60. CD3-positive celli 
are demonstrated by their green fluorescence. CDw60 cells arr 
demonstrated by their red fluorescence. Double photographic 
exposure demonstrates that CD3+ and CDw60+ cells fluoresc-
ing both colors appear orange, demonstrating that nearly all the 
T ce lls in the skin co-express CDw60. Bar, 210 11m. b) Indirect 
immunofluorescence of CDw60 on peripheral blood from a 
patient with CTCL. Leji, phase microscopy; right, labeled by 
anti-CDw60 with rhodamine-co~ugated goat anti-mouse 
IgM. Bar, 45 11m. 
using recombinant IL-2, anti-C03, anti-TCR-l, anti-C02, or 
anti-C028 as single stimuli. In contrast, stimulation with anti-
COw60 resulted in a brisk proliferation in three of four patients (Fig 
4, cross-hatched bars) . 
Because all of the above ligands, except anti-COw60, activate T 
cells weakly when used as single stimuli, all of the mitogenic lectins 
and antibodies were co-cultured with PMA. For optimal activation 
through the C02 pathway, a mitogenic pair of anti-C02 antibodies 
were used. 
In combination with PMA, all ligands induced activation of the T 
cells, but anti-COw60 still demonstrated an enhanced response rela-
tive to the mitogenic lectins and anti-TCR/C03 in all four patients 
studied. However, the mitogenic pair of anti-C02 plus PMA and 
anti-C028 plus PMA also demonstrated enhanced activation rela-
tive to mitogenic lee tins and anti-TCR/C03 (Fig 4, stippled bars). 
Hind III Digest 
8-
6.5-
.5-
Eco R1 Digest 
12-
4.2-
Figure 2. Southern blot analysis of a CTCL skin lesion and the peripheral 
blood from patient 1. DNA samples were digested with HilldIII or EcoRl 
and hybridized to the TCR-Cp probe to detect TCRp-chain gene rearrange-
ments. Dasiles, molecular sizes in kilobases of germ-line bands. As indicated 
on the Southern blot, the same rearranged bands both in the blood and the 
skin following HindIII digest (arrows) and the near disappearance of the 
12-kbp band both in the blood and skin following EcoR1 digest demonstrate 
that the majority of the T cells in the blood and in the skin have the same 
T-cell receptor gene rearrangement and thus belong to the same clone. 
Antigen-Independent Pathways Dominate in Patients with 
CTCL Relative to MNC from healthy individuals, MNC from 
patients with CTCL reacted only weakly to stimulation by mito-
genic lectins or anti-TCR/C03. However, activation by anti-
COw60, anti-C02, and anti-C028 resulted in strong activation 
(Fig 5) . Responses above the line indicate a more potent response 
from the patients with CTCL compared with healthy subjects. 
Thus, relative to T cells from healthy subjects , activation ofT cells 
from patients with CTCL by antigen-independent pathways re-
sulted in enhanced activation. 
Capacity of Stimulated T Cells to Secrete y-Interferon Is Sig-
nificantly Diminished in T Cells from Patients with CTCL 
Compared with Healthy Subjects Certain differentiated T-
cell subsets produce y-interferon in response to activation (Thl ), 
whereas others lack y-interferon production (Th2) [18]. Because T 
cells from patients with CTCL proliferate in response to anti-
COw60, w e asked whether proliferation was associated with release 
of y-interferon. T cells from the patients and a healthy control 
group were incubated with either anti-COw60 or a mitogenic pair 
of anti-C02 antibodies. Anti-C028 was co-cultured with PMA to 
obtain optimal stimulation. 
Table IV. Immunophenotyping of Peripheral Blood 
Mononuclear Cells· 
Patient 
2 3 4 Control Subjeco 
CD4+ 94 86 85 30 41 ± 5 
CD8+ 2 4 7 19 17 ± 2 
CD2+ 62 12 73 48 69 ±4 
CD3+ 61 81 72 40 57 ± 10 
TCR+ 2 86 71 34 54 ± 8 
CD19+ 3 3 2 1 9±2 
CDw60+b 95 98 85 96 28 ±7 
CD25+ 0 0 0 3 O±O 
HLA-DR+ 4 14 8 37 30±3 
Leu-M3+ 3 3 4 35 15 ± 2 
• Number of positive cells relative to total cell number. 
• Number of C Dw60 positive cells relative to total number of positive T cells dettl-
mined by CD2 and CD3 staining cells. 
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Figure 3. a) Southern blot analysis of a peripheral blood T ·cell line ob-
uined from patient 1 (E). The analysis was performed on the cells after 1-4 
'/leeks in culture. DNA samples were digested with HitJdIlI and were hybrid-
ized co the TCR-CP probe to detect TCR p-chain gene rearrangements. 
ArroU/, rearranged band. The malignant clone is gradually replaced by other 
clones as indicated by the disappearance of the TCR gene rearrangement. 
ume Nt shoVIIs size markers (23, 9.4, 6.6, 4.2, 2.3 kb). b) T-cell lines were 
initiated from both patient 1 (cross-hatched bars) and a healthy control subject 
{Itriped bars}. After 1-3 weeks in culture, analysis of CDw60 antigen was 
periormed on a Becton Dickinson fluorescence-activated cell sorter IV flow 
cywmeter. Anti-CDw60 was identified with fluorescein-conjugated goat 
wei-mouse jlnmunoglobulin. Analysis was performed on 10,000 cells, and 
die acquired data are expressed as percent of CDw60+ cells. 
It is surprising that despite the brisk proliferation induced by 
CDw60, CD2, or CD28, T cells from patients with CTCL did not 
release detectable amounts of Y-interferon, a secretion pattern that 
resembles Th2 cells (Fig 6). In contrast, normal blood T cells all 
dtmonstrated inducible y-interferon production (Fig 6). 
DISCUSSION 
We recently demonstrated that antigen-presenting Langerhans 
cells in lesional CTCL epidermis are both in an abnormal state of 
diffe rentiation characterized by an aberrant expression of CD36 and 
';' 
o 
:E 
a... 
u 
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PHA CONA PWM r1L-2 CD3 TCR C02 CD28 CDw60 
1-11 TOGENS 
Figure 4. Fifty-thousand MNC from each patient were stimulated with 
various mitogens and T -cell- activating surface molecules, as single stimuli 
(cross-hatched bars) or in combination with PMA (stippled bars). The resultant 
T-cell proliferation was measured as TdR incorporation after 48-h incuba-
tion. Data are expressed as mean cpm ± SEM of experil11ents with four 
patients with CTCL. 
CD1b [19-21] and in a hyperstimulatory functional state capable of 
activating autologous CD4+ T cells in the absence of added exoge-
nous antigens [4] . Efficient blockade of T-cell proliferation was 
achieved with a blocking antibody to major histocompatibility 
complex class II molecules, indicating that the primary signal was 
transmitted through the TCR [4] . In contrast, attempts to stimulate 
and propagate malignant T cells ill vitro from human T-cell lym-
photropic virus-l- negative patients with CTCL have been ex-
tremely difficult [12-17, 22 - 25], with a few exceptions [26,27]. 
We therefore suggest that TIL may be responsive to antigen-recep-
tor signaling provided by hyperstimulatory Langerhans cells 
present in CTCL epidermis. On the other hand, the malignant 
clone may be stimulated preferentially through alternative activa-
tion pathways, such as CD2, CD28, and CDw60. 
Our results in this study demonstrate that the antigen-indepen-
dent T-cell-activating molecule CDw60 is highly expressed on 
PATIENTS/CONTROLS CPM .. 100 
148 
150 
1215 
t- 100 
Z 
W 
0 75 
cr. 
W 
0.. 
50 
215 
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PH" CON" PWM CD3 TCR C02 CD28 CDw60 
MITOGENS+PMA 
Figure 5. Proliferative response of 50,000 MNC cells from four patients 
with CTCL compared with that of 50,000 MNC from four healthy subjects. 
The y-axis demonstrates the percent ofTdR incorporation of the CTCL T 
cells relative to healthy subjects (n = 4). 
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Figure 6. Fifty-thousand MN C from patients with CTCL and a healthy 
control group were incubated with anti-CDw60, a pair of C02 antibodies, 
or anti-CD28. The latter was co-cul tured with PMA. T he x-axis is split into 
sections: 1- 4, response of each individual patient with CTCL; CON-
TROLS, group response of normal control subjects. Left bars in each section 
demonstrate the resulting T-cell proli fera tion measured as TdR incorpora-
tion, shown as cpm on the y-axis; right bars in each section represent the 
release of y-interferon from the T-cell supernatant, measured by an ellzymc-
linked immunosorbent assay kit and shown on the y-axis as U 1m!. 
malignant'T cells in both the skin and peripheral blood of patients 
with CTCL (Tables III and IV; Fig 1a,b) . In contrast to the high 
frequency of COw60 on malignant CTCL T cells, ill vitro-
generated non-malignant T IL in patients with CTCL have a nor-
mal level of COw60 expression (Fig 3b) . T he diminished expres-
sion of COw60 on T IL was not due to the cul ture procedure because 
T-cell clones derived from psoriatic skin maintained a high fre-
quency of COw60 expression, refl ecting high ill villo expression 
[28]. 
In both normal T cells [5) and synovial fluid T cells [29), COw60 
is expressed on a proportion of all T-cell subsets examined, includ-
ing C04+, C08+, C045RO+' and C045RA+ T cells. COw60 
appears to be expressed on a somewhat higher percentage of 
C045RO+ cells than C045RA+ cells among T cells isolated from 
peripheral blood, but expression on the CD4+ and C08+ subsets 
was comparable. T he level of COw60 expression observed on 
CTCL cells has not been found thus far on any normal peripheral 
blood T -cell subsets. Furthermore, malignant T cells that lack C D4 
can in some cases express high levels of COw60, such as variants of 
the HSB2 leukemic T cell line [5). In addition, C Dw60 is not a 
marker for T-cell activation because expression of CDw60 is not 
induced by activation of T cells [5]. 
The high frequency of C Dw60+ T cells in CTCL was correlated 
with a brisk response to stimulation with anti-C Dw60 relative 
to anti-TCR/ CD3 and mitogenic lectins. In addition, relative to 
T cells from healthy individuals, acti va tion of T cells from pa-
tients with CT CL by COw60, C 0 2, and C828 resulted in en-
hanced activation. It coul d be argued that these fin dings are due to 
a preferential activation of CD4+CD45RO+ T cells relative 
to C04+CD45RA+ by anti-COw60; however, because anti-
CD3 preferentially activates CD4+C045RO + T cells in normal 
subj ects [30) , and we found a decreased response to anti-C D 3 in 
patients with CTCL who demonstrate an enhanced number of 
CD4+C045RO+ T cells, a simple numerical explanation cannot 
account fo r the observed differences. In normal subjects, COw60 is 
mitogenic fo r peripheral blood T cells only in the presence of acces-
sory cells [5) . It could be argued that the depressed response to 
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mitogenic lectins and T C R-complex - mediated activation was due 
to a lack of accessory cells in the peripheral blood of patients with 
CT C L. However, inadequate accessory cell function cannot explain 
the differential response because anti-CDw60 induced a larger re-
sponse than the mitogenic lectins and anti-TCR/CD 3, even in the 
presence of PMA. PMA bypasses accessory cell requirements by 
directly stimulatin g calcium and phospholipid-dependent protein 
kinase-C activity [31) and thereby permits direct assessment of T-
cell proliferation capacity. Thus, T cells from patients with CT CL 
exist in a distinct activation state. U sing PMA, not only COw60 but 
also other ac tivating molecules, C0 2 and C028, represent signa-
ling mechanisms in the antigen-independent activation of CTCL 
T cells. 
D espite proliferation induced by anti-CDw60, anti-C02, and 
anti-C D 28, no y-interferon was produced by the patients' T cells. 
Because the patients with CTC L expressed a high percentage of 
" memory" T cells, these results were not expected because y-inter-
feron is preferentially synthesized by the "memory" T-cell popula-
tion on stimulation [32) . Our findings may explain the lack of 
epidermal expression of IC AM-1 in these patients ill vivo because 
this molecule is induced by y-interferon. Our findings are in agree-
ment with a previous report concerning one patient with Sezary 
syndrome in whom stimulation of leukemic blood T cells resulted 
in a markedly diminished amount of y-interferon release compared 
with healthy subjects (33). 
Because stimulation through antigen-independent pathways, 
such as C Ow60, C02, and C028, on CT C L T cells results in brisk 
activation , these pathways may be operative in the lesional skin 
milieu and may contribute to ill Ilivo ch ronic clonal T-cell activa-
tion, even in absence of antigen. Cooperation between antigen-de-
pendent and antigen-independent T-cell activation is also possible. 
This is highlighted by a recent hypothesis that C028 and B7/ BB-l 
are a receptor/ ligand pair responsible for an antigen-presenting 
cell - derived co-stimulatory signal involved in antigen-specibc 
IL-2 production by T cells [34) . LFA-3 and B7 , which are ligands 
for C 0 2 and C 0 28, respectively, are clearly abundantly expressed 
in the skin. The natural ligand for COw60 is still unknown; h ow-
ever, the presence of COw60-positive T cells in the CTCL and 
psoriatic skin , inflammatory synovium, and thymic tissue [35] may 
be explained by a ligand for COw60 in these compartments. Of 
interest, malignant human T -cell lines without affini ty to the skin 
only weakly express COw60 or lack this antigen altogether [5). 
Thus, diminished responsiveness of the malignant clone to T CR-
mediated signaling may explain the difficul ty many investigators 
have had in propagating the clone in vitro and may also indicate 
escape from normal regulation. Activation of CTCL T cells via 
anti gen-independent pathways may be a new approach to under-
stand the immunoregulatory events in CTCL. 
This ill vestiga tioll was sllpported by gra II ts frOIll the Dallish Callcer Society, theMax 
Fodgaa rds FO lllldatioll , alld the DOllish Medica l Research COl/llcil, CopeIl J, agerl, 
DW/llark; alld ti,e Veterall s Adlllillistratioll , AIIII A rbor, Ml. 
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